tert-butyl (S)-(1-((5-bromopyridin-3-yl)oxy)-3-phenylpropan-2-yl)carbamate | 882169-82-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (S)-(1-((5-bromopyridin-3-yl)oxy)-3-phenylpropan-2-yl)carbamate
• 英文别名: [(S)-1-(5-Bromo-pyridin-3-yloxymethyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester；tert-butyl N-[(2S)-1-(5-bromopyridin-3-yl)oxy-3-phenylpropan-2-yl]carbamate
• CAS: 882169-82-6
• 化学式: C₁₉H₂₃BrN₂O₃
• 分子量: 407.307
• InChiKey: INCGEYMERWCJKG-INIZCTEOSA-N

物化性质

• 沸点：
  534.4±50.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-(1-((5-bromopyridin-3-yl)oxy)-3-phenylpropan-2-yl)carbamate 在 盐酸 、 tris(dibenzylideneacetone)dipalladium (0) 、 sodium cyanoborohydride 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 溶剂黄146 、 三氟乙酸 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 10.0h， 生成 [5-((S)-2-Amino-3-phenyl-propoxy)-pyridin-3-yl]-pyridin-3-ylmethyl-amine
  参考文献：
  名称：

  Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer

  摘要：

  Structure-based design and synthesis of the 3,4'-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC50 of 1.3 nM against Akt1. Compound 13a shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to marginal selectivity against closely related kinases in the AGC and CMGC families. Moreover, 13a demonstrates potent cellular activity comparable to staurosporine, with IC50 values of 0.42 and 0.59 mu M against MiaPaCa-2 and the Akt1 overexpressing FL5.12-Akt1, respectively. Inhibition of phosphorylation of the Akt downstream target GSK3 was also observed in FL5.12-Akt1 cells with an EC50 of 1.5 mu M. The X-ray structures of 12 and 13a in complex with PKA in the ATP-binding site were determined. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.12.065
• 作为产物：
  描述：

  3-溴-5-羟基吡啶 、 N-Boc-L-苯丙氨醇 在 三乙胺 、 对甲苯磺酰氯 、 potassium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 以45.7 %的产率得到tert-butyl (S)-(1-((5-bromopyridin-3-yl)oxy)-3-phenylpropan-2-yl)carbamate
  参考文献：
  名称：

  发现新型 N-(5-(Pyridin-3-yl)-1H-indazol-3-yl)benzamide 衍生物作为有效的细胞周期蛋白依赖性激酶 7 抑制剂，用于治疗常染色体显性多囊肾病

  摘要：

  最近的证据表明，CDK7 是常染色体显性多囊肾病 (ADPKD) 治疗的新型潜在药物靶点。在此，在结构分析的基础上，设计了具有新型支架的命中化合物3，并通过合理的设计策略进行了后续的药物化学工作，以提高 CDK7 抑制剂的效力和选择性。代表性化合物B2有效抑制 CDK7，IC 50值为 4 nM，并显示出对 CDK 的高选择性。在体外Madin-Darby 犬肾囊肿模型中，化合物B2显示出抑制囊肿生长的高效力，并且表现出比 THZ1 更低的细胞毒性。此外，化合物B2在体外胚胎肾囊肿模型和体内ADPKD 小鼠模型中抑制肾囊肿发展也非常有效。这些结果表明化合物B2代表了一种有前途的先导化合物，值得进一步研究以发现新的 ADPKD 治疗剂。

  DOI：

  10.1021/acs.jmedchem.2c01334

文献信息

• Kinase inhibitors
  申请人：——

  公开号：US20030187026A1

  公开（公告）日：2003-10-02

  Compounds having the formula 1 are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

  具有以下化学式的化合物对抑制蛋白激酶很有用。还公开了抑制蛋白激酶的组合物以及在患者中抑制蛋白激酶的方法。
• Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase
  作者：Sheela A. Thomas、Tongmei Li、Keith W. Woods、Xiaohong Song、Garrick Packard、John P. Fischer、Robert B. Diebold、Xuesong Liu、Yan Shi、Vered Klinghofer、Eric F. Johnson、Jennifer J. Bouska、Amanda Olson、Ran Guan、Shayna R. Magnone、Kennan Marsh、Yan Luo、Saul H. Rosenberg、Vincent L. Giranda、Qun Li

  DOI：10.1016/j.bmcl.2006.04.046

  日期：2006.7

  Based on lead compounds 2 and 3 a series of 3,5-disubstituted pyridines have been designed and evaluated for inhibition of AKT/PKB. Modifications at the 3 position of the pyridine ring led to a number of potent compounds with improved physical properties, resulting in the identification of 11g as a promising, orally active Akt inhibitor. The synthesis, structure-activity relationship studies, and pharmacokinetic data are presented in this paper. (c) 2006 Elsevier Ltd. All rights reserved.
• Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension
  作者：Gui-Dong Zhu、Viraj B. Gandhi、Jianchun Gong、Sheela Thomas、Keith W. Woods、Xiaohong Song、Tongmei Li、R. Bruce Diebold、Yan Luo、Xuesong Liu、Ran Guan、Vered Klinghofer、Eric F. Johnson、Jennifer Bouska、Amanda Olson、Kennan C. Marsh、Vincent S. Stoll、Mulugeta Mamo、James Polakowski、Thomas J. Campbell、Ruth L. Martin、Gary A. Gintant、Thomas D. Penning、Qun Li、Saul H. Rosenberg、Vincent L. Giranda

  DOI：10.1021/jm0701019

  日期：2007.6.1

  Compound 7 was identified as a potent (IC50 = 14 nM), selective, and orally bioavailable (F = 70% in mouse) inhibitor of protein kinase B/Akt. While promising efficacy was observed in vivo, this compound showed effects on depolarization of Purkinje fibers in an in vitro assay and CV hypotension in vivo. Guided by an X-ray structure of 7 bound to protein kinase A, which has 80% homology with Akt in the kinase domain, our efforts have focused on structure-activity relationship (SAR) studies of the phenyl moiety, in an attempt to address the cardiovascular liability and further improve the Akt potency. A novel and efficient synthetic route toward diversely substituted phenyl derivatives of 7 was developed utilizing a copper-mediated aziridine ring-opening reaction as the key step. To improve the selectivity of these Akt inhibitors over other protein kinases, a nitrogen atom was incorporated into selected phenyl analogues of 7 at the C-6 position of the methyl indazole scaffold. These modifications resulted in the discovery of inhibitor 37c with greater potency (IC50 = 0.6 nM vs Akt), selectivity, and improved cardiovascular safety profile. The SARs, pharmacokinetic profile, and CV safety of selected Akt inhibitors will be discussed.
• Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation
  作者：Qun Li、Tongmei Li、Gui-Dong Zhu、Jianchun Gong、Akiyo Claibone、Chris Dalton、Yan Luo、Eric F. Johnson、Yan Shi、Xuesong Liu、Vered Klinghofer、Joy L. Bauch、Kennan C. Marsh、Jennifer J. Bouska、Shannon Arries、Ron De Jong、Tilman Oltersdorf、Vincent S. Stoll、Clarissa G. Jakob、Saul H. Rosenberg、Vincent L. Giranda

  DOI：10.1016/j.bmcl.2005.12.017

  日期：2006.3

  A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4'-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined. (C) 2005 Elsevier Ltd. All rights reserved.
• US6831175B2
  申请人：——

  公开号：US6831175B2

  公开（公告）日：2004-12-14